Metallic Radionuclides: Development and Application in Radiopharmaceutical Area

Dear Colleagues,

Radiopharmaceuticals are powerful tools for the diagnosis and treatment of oncological, cardiovascular, or neurodegenerative diseases. In addition, the opportunity of combining Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) radio-imaging and internal radiotherapy using different radionuclides incorporated in identical structures can make possible real theranostic applications, truly realizing the long-awaited “personalized medicine”.

Advances in the radiopharmaceutical field and recent technological innovation have opened perspectives to bring unique solutions to clinical demands by providing better diagnosis and more efficient therapies.

Metal radionuclides offer unprecedented features, i.e., decay modes, branching ratios, and emission types, a broad range of half-lives and energies, as well as a great variety of chemistries. Moreover, the availability of several radiometals allows for careful picking of the particular nuclear properties necessary for a number of different applications.

This is why current research for radiopharmaceutical applications of metallic radionuclides is extremely intensive, as evidenced by the plethora of highly valued scientific articles that are published every day in the field.

Given this perspective, this Special Issue of Molecules, titled “Metallic radionuclides: development and application” will accept reviews and research papers focusing on recent advances in the following topics:

• Production, separation, and purification of metallic radionuclides for radiopharmaceutical applications;
• Synthesis and preclinical/clinical evaluation of metal-based radiopharmaceuticals proposed as diagnostic/multimodal diagnostic, therapeutic, and theranostic agents;
• Synthesis and preclinical/clinical evaluation of metal-based, alpha emitter radiopharmaceuticals;
• Individualized dosimetry for metal-based theranostics.

Dr. Cristina Bolzati
Dr. Nicola Salvarese
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.